real peptides FAQ

Request it explicitly before purchase, and if unavailable, source VIP from a different supplier. Mass spectrometry confirmation is not optional for research peptides. It verifies that the synthesized molecule matches the intended amino acid sequence and that no truncated or modified peptides are present above trace levels. Suppliers who claim proprietary synthesis methods prevent data sharing or offer only generic purity percentages are either using third-party manufacturers they cannot vouch for or are reselling material of unknown provenance. Legitimate research suppliers like Real Peptides provide ESI-MS traces specific to each production lot because this is standard quality assurance in peptide manufacturing, not a premium service.

Reassess bioavailability first. If reconstitution was performed incorrectly or the peptide was stored above 8°C at any point, protein denaturation renders the compound inactive with no visual indication of degradation. Verify amino-acid sequencing and purity certificates from the supplier. Peptides synthesised without HPLC purification may contain deletion sequences that trigger immune responses rather than immune modulation. If bioavailability is confirmed, the mechanism may not match the disease phenotype. Thymosin alpha-1 won't reduce mucosal inflammation in IBD, and VIP won't restore T-regulatory populations in rheumatoid arthritis. The four-week timeframe is appropriate for mucosal peptides like VIP but insufficient for thymic peptides like thymosin alpha-1, which require 8–12 weeks to measurably shift T-regulatory cell populations.

Semax or Cerebrolysin become primary candidates when stress manifests as brain fog, impaired working memory, or difficulty concentrating. Semax's BDNF upregulation directly counters stress-induced hippocampal atrophy. The mechanism behind memory consolidation failures many chronic stress sufferers experience. Start with Semax amidate 300–600mcg intranasal daily for 28 days. If cognitive symptoms include executive function impairment (decision-making, task-switching), consider Dihexa. A research peptide demonstrating potent synaptogenic effects through hepatocyte growth factor (HGF) pathway activation. Animal models show Dihexa enhances dendritic spine density by 40–50% within 14 days at 5mg/kg oral dosing.

Yes, and post-surgical healing is one of the most promising research contexts for these peptides. Surgical repair mechanically approximates the torn tendon ends, but biological healing—re-establishing blood supply, forming new collagen matrix, and restoring tensile strength—still depends on the same inflammatory, proliferative, and remodeling phases. Animal studies using Achilles tendon transection with surgical repair demonstrate that BPC-157 administered post-operatively reduces adhesion formation (fibrous tissue that binds the tendon to surrounding structures, limiting range of motion) and accelerates return to load-bearing activity. TB-500's angiogenic properties become critical in the surgically repaired zone, where blood supply is initially disrupted.

VIP access includes priority support for institutional documentation requests, including third-party purity certificates, endotoxin testing results, and synthesis facility compliance attestations. Standard-tier requests typically process within 7–10 business days. VIP requests receive 48-hour turnaround with direct coordination between Real Peptides' quality team and your institutional procurement or grants office. This matters during grant application deadlines or IRB review cycles where vendor qualification documentation gates protocol approval. We've seen research teams lose 3–4 week protocol approval windows waiting for standard documentation processing. VIP priority support eliminates that bottleneck and allows simultaneous vendor qualification and protocol submission rather than sequential processing.

Combine with caution and monitor for over-suppression. Thymalin upregulates regulatory T-cells, which secrete IL-10 and TGF-β to dampen effector T-cell activity. TNF-α inhibitors (etanercept, adalimumab) block a key pro-inflammatory cytokine downstream of T-cell activation. The combined effect could suppress immune responses beyond the target autoimmune pathway, increasing infection risk in research subjects. Preclinical protocols frequently use a washout period of 4–8 weeks between biologic therapy and peptide introduction to isolate effects.

Discard it immediately. Cloudiness indicates either microbial contamination (if non-bacteriostatic water was used) or precipitation of degraded molecular fragments that have lost solubility—neither scenario produces valid research data. SS-LUP-332 reconstituted properly in DMSO or bacteriostatic water remains clear and colorless at 2–8°C for up to 30 days. If cloudiness appears within the first 48 hours, the issue is almost always incorrect solvent choice or contamination during reconstitution. If it appears after two weeks of proper storage, temperature excursions during handling are the likely cause—even briefly leaving the vial at room temperature during repeated draws can initiate precipitation.

SS-LUP-332 exercise gene program activation restores mitochondrial function in disease models characterized by oxidative deficiency. In db/db mice (a type 2 diabetes model with severe insulin resistance), SS-LUP-332 administration increased skeletal muscle mitochondrial respiration by 60–80% and improved glucose tolerance comparable to chronic exercise training. Critically, the compound reversed markers of mitochondrial dysfunction—restoring mitochondrial membrane potential, reducing reactive oxygen species production, and normalizing ATP synthesis rates—that diet or insulin sensitizers alone did not correct. This indicates PPARδ activation addresses the underlying mitochondrial pathology driving metabolic inflexibility in insulin-resistant states, not just compensating for downstream glucose handling defects.

Measure β-galactosidase activity and ATP synthesis rate in your baseline tissue samples. β-galactosidase (senescence-associated β-gal, SA-β-gal) is a biomarker of senescent cell accumulation. If your model shows elevated SA-β-gal+ cells, FOXO4-DRI is appropriate. If ATP synthesis is reduced (measured via Seahorse XF analyzer or Clark electrode respirometry) but SA-β-gal is normal, SS-31 targets the relevant pathway. The biomarker profile determines peptide selection. Many aged tissue models show both senescent cell accumulation and mitochondrial dysfunction. In that case, test both peptides in separate cohorts to determine which pathway contributes more to your phenotypic endpoint.

Combine peptides with non-overlapping mechanisms. Growth hormone secretagogue plus mitochondrial protectant plus senolytic. A common research stack pairs Ipamorelin (GH secretion for proteostasis and body composition), MOTS-C (mitochondrial function and metabolic efficiency), and Thymosin Alpha-1 (immune restoration). This addresses four hallmarks of aging. Loss of proteostasis, mitochondrial dysfunction, altered intercellular communication, and immunosenescence. Without redundant pathway activation or competitive receptor binding.

Stacking peptides with distinct mechanisms—such as a GLP-1 agonist for appetite suppression plus an AMPK activator for fat oxidation—can produce additive effects in research models, but human trial data is limited and safety profiles become unpredictable. Combining two GLP-1 pathway agonists (e.g., semaglutide + tirzepatide) provides no additional benefit and doubles GI side effect risk. However, combining a GLP-1 agonist with a mechanistically distinct compound like 5-Amino-1MQ (AMPK/NNMT pathway) or AOD9604 (beta-3 adrenergic pathway) targets different metabolic nodes—one reducing intake, the other increasing oxidation. No published trials have tested this combination in humans, so any stacking protocol remains investigational and should be conducted with appropriate oversight and monitoring.

Switch to SS-31 (Elamipretide) immediately. Epithalon targets telomerase, not mitochondria. Telomerase activation won't restore cardiolipin integrity or cristae structure, so ATP synthesis measurements and oxygen consumption rates will show no change regardless of dosing or purity. The experimental model and peptide mechanism are mismatched. SS-31 at 1–4mg/kg daily subcutaneous is the appropriate compound for mitochondrial biogenesis, respiratory complex activity, and ROS production endpoints. Our team has reviewed this exact scenario across dozens of longevity labs. The problem is never the peptide quality, it's mechanism mismatch.

Consider three variables: dose escalation speed, meal composition, and individual GLP-1 receptor density. If nausea persists beyond 8 weeks at a stable dose, the titration schedule may have been too aggressive—gastric GLP-1 receptors need 4-6 weeks to downregulate at each dose increase. Slowing the escalation to 6-week intervals instead of 4 often resolves persistent symptoms. Meal composition matters: high-fat meals exacerbate delayed gastric emptying and increase nausea incidence. Switching to smaller, lower-fat meals (15-20g fat per meal instead of 30-40g) reduces symptom severity in 60-70% of cases. If symptoms persist despite slower titration and dietary modification, the individual may have higher baseline GLP-1 receptor density in gastric tissue—a genetic variability that makes them more susceptible to GI effects at any dose. In research contexts, this is a subject-specific variable; in therapeutic use, it may require switching to a different peptide or discontinuing.

Discard the vial and request replacement. Lyophilized peptides must be stored at −20°C before reconstitution; once mixed with bacteriostatic water, they require refrigeration at 2–8°C. Temperature excursions above 8°C. Even for a few hours. Cause irreversible protein denaturation. The peptide's tertiary structure unfolds, destroying receptor binding sites and eliminating biological activity. There's no visual indicator of denaturation; potency loss is silent. Research institutions using temperature-compromised peptides generate false-negative results, wasting months of work and research funding.

Store all lyophilized peptides at −20°C in desiccated conditions; once reconstituted with bacteriostatic water, store at 2–8°C and use within 28 days for maximal stability. Peptides with free N-termini or C-termini are particularly susceptible to exopeptidase degradation. Adding protease inhibitors to reconstitution buffer can extend functional half-life in vitro. For in vivo studies, subcutaneous or intraperitoneal injection delivers peptides into circulation where endogenous peptidases (DPP-4, neprilysin) immediately begin degradation. GLP-1 analogs like semaglutide resist DPP-4 cleavage through amino acid substitutions and fatty acid conjugation that extends half-life from minutes (native GLP-1) to days. Validate peptide integrity using HPLC or mass spectrometry before starting a study. Degraded peptides produce irreproducible results and waste experimental time.

Discard it immediately. Cloudiness indicates protein aggregation, precipitation, or bacterial contamination—all of which render the solution unsuitable for controlled biological research. Properly reconstituted BPC-157 and TB-500 should remain clear and colorless throughout the 28-day refrigerated storage window. Aggregation occurs when peptides are exposed to temperature excursions, freeze-thaw cycles, or vigorous shaking during reconstitution (which denatures the protein structure through mechanical stress). Always reconstitute by gently tilting the vial and allowing the bacteriostatic water to run down the side wall, then swirl gently—never shake.

Do not mix multiple peptides in the same vial—administer each peptide from its own solution to prevent peptide-peptide interactions that could alter solubility, charge distribution, or receptor binding. Some researchers combine Selank and Semax in stress models to target both anxiolytic and cognitive pathways simultaneously; this is scientifically valid but requires separate syringes and injection sites. Mixing peptides before administration risks precipitation if their isoelectric points differ significantly, and it eliminates the ability to titrate doses independently. If investigating synergistic effects, co-administer from separate solutions at time intervals appropriate to each peptide's pharmacokinetics—Selank peaks within 30–60 minutes post-administration, while Semax shows peak BDNF upregulation at 2–4 hours.

Extend your monitoring intervals and add organ-specific biomarkers beyond the published panels. Include liver function tests (ALT, AST, ALP, GGT) at weeks 4, 8, and 12, not just at endpoint—this captures delayed-onset hepatotoxicity that may not appear within 28 days. Add renal injury biomarkers (KIM-1, NGAL) if your model involves metabolic stress, diabetes induction, or high-fat diet, all of which can amplify nephrotoxic susceptibility. The absence of chronic safety data means you are operating outside the validated safety window, so incremental monitoring is not optional—it is the only way to detect adverse effects before they become irreversible.

Check three variables before concluding the peptide is inactive: (1) administration route and timing relative to measurement (intranasal Semax measured 30 minutes post-dose may show no effect because peak hasn't occurred yet), (2) study duration relative to mechanism (Cerebrolysin measured at 48 hours post-dose hasn't had time to upregulate neurotrophic factors), (3) storage conditions (lyophilised peptides stored above −20°C or reconstituted peptides stored above 8°C degrade, producing inactive fragments that HPLC may not distinguish from intact peptide without sequencing). We've seen researchers attribute 'no effect' to low potency when the actual issue was measuring Dihexa's structural effects at 72 hours. Before spine density increases. If the peptide's mechanism requires 10–14 days to produce measurable outcomes and you measure at day 3, the protocol failed, not the peptide.

Switch to lipolytic peptides like AOD9604 or growth hormone secretagogues like CJC-1295/Ipamorelin, which target visceral fat through adrenergic receptor activation rather than gastric mechanisms. GI side effects—nausea, vomiting, diarrhea—occur in 30–45% of patients during GLP-1 dose titration because these receptors are highly expressed in gastric and intestinal tissue; the slower gastric emptying that contributes to satiety also triggers nausea. AOD9604 stimulates hormone-sensitive lipase in adipocytes without affecting GI motility, producing fat loss without the gastric side effects. Clinical trials showed no significant difference in GI adverse events between AOD9604 and placebo, making it a viable alternative for patients who cannot tolerate GLP-1 therapy.